TAO Synergies Inc. (TAOX) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. TAO Synergies Inc. (formerly Synaptogenix, Inc.) has pivoted from a biopharmaceutical company to a cryptocurrency treasury strategy focused on the Bittensor (TAO) token. The company launched "The TAO Daily" media platform and formed a subsidiary, TAOX Florida Inc., to facilitate its crypto operations. As of the reporting date, the company holds approximately 50,363 TAO tokens.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue (Staking) | $203,371 | $0 | $207,333 | $0 |
| Operating Expenses | $2,002,871 | $1,978,044 | $6,111,831 | $5,250,505 |
| Net Loss | $(3,923,247) | $(5,742,013) | $(21,054,156) | $(7,222,021) |
| Loss Per Share (Basic) | $(1.56) | $(5.01) | $(9.84) | $(6.63) |
| Cash & Equivalents | $1,445,427 (as of Sept 30, 2025) | |||
| Digital Assets (TAO) | $15,381,039 (as of Sept 30, 2025) | |||
| Total Assets | $18,358,987 (as of Sept 30, 2025) | |||
| Total Liabilities | $1,690,046 (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Generation: The company generated $203,371 in staking revenue for Q3 2025, compared to zero in the prior year, driven by its new TAO treasury strategy.
- Unrealized Losses: A significant unrealized loss on digital assets of $2,382,129 was recorded in Q3 2025 due to market volatility in TAO prices. This contributed to a YTD net loss of $21.05 million, compared to $7.22 million in the prior year.
- Expense Shifts: Research and Development (R&D) expenses decreased by 75.6% to $54,388 in Q3 2025 as the company discontinued its MS clinical trial with Cleveland Clinic. Conversely, General and Administrative (G&A) expenses increased by 71.4% to $1.95 million, driven by legal fees related to restructuring and non-cash stock-based compensation.
- Balance Sheet: Cash decreased from $17.7 million (Dec 31, 2024) to $1.4 million (Sept 30, 2025) due to the purchase of $17.6 million in TAO tokens. Total liabilities decreased significantly from $10.96 million to $1.69 million, primarily due to the redemption and conversion of Series C Preferred Stock and the reclassification of warrant liabilities to equity.
Guidance, Outlook, and Risks
- Strategy: Management maintains a "long-only" TAO accumulation policy with no formal cap on treasury allocation. The company plans to continue staking TAO for yield and capital appreciation.
- Liquidity: Management believes current cash and TAO holdings (approx. $34 million total value) are sufficient for operations for the next 12 months. However, additional capital will likely be required to pursue the full treasury strategy.
- Subsequent Financing: In October 2025, the company closed a Series E Preferred Stock financing, selling 11,000 shares and warrants for proceeds to support operations.
- Key Risks:
- Volatility: Operating results are heavily dependent on the price of TAO, which is highly volatile.
- Regulatory: Uncertainty regarding the classification of TAO as a security and potential regulatory actions against crypto assets.
- Operational: Reliance on third-party custodians (BitGo) and validators (Yuma) introduces counterparty and cybersecurity risks.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, including inadequate segregation of duties and ineffective IT general controls.
Investor Verification Checklist
- TAO Valuation: Verify the current market price of TAO and the company's specific holdings to assess the unrealized loss impact on the balance sheet.
- Cash Runway: Confirm the burn rate given the low cash balance ($1.4M) relative to the $17.6M invested in crypto assets.
- Warrant Liability Reclassification: Review the accounting treatment for the reclassification of Series C and D warrant liabilities to equity and the associated non-cash losses recognized.
- Internal Controls: Assess the remediation plan for the disclosed material weaknesses in internal controls over financial reporting.
- Series E Terms: Review the terms of the October 2025 Series E financing, including conversion prices and dividend rates, to understand potential dilution.